Fasenra

Add-on maintenance in adults w/ severe eosinophilic asthma (blood eosinophil count ≥300 cells/microliter or ≥150 cells/microliter if on oral corticosteroid treatment) inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.

SC Inj into thigh, abdomen or upper arm. Recommended dose: 30 mg every 4 wk for 1st 3 doses, then every 8 wk thereafter.

Hypersensitivity.

Acute systemic reactions including anaphylactic & hypersensitivity reactions (eg, urticaria, papular urticaria, rash) may occur w/in hr of administration or delayed onset. Permanently discontinue treatment & initiate appropriate therapy in the event of hypersensitivity reaction. Discontinue treatment if patients become infected while receiving Fasenra & do not respond to anti-helminth treatment, until infection resolves. Not to be used to treat acute asthma exacerbations. Not to be inj into areas where skin is tender, bruised, erythematous, or hardened. Monitor patients for appropriate time after administration of treatment. History of anaphylaxis unrelated to treatment. Patients w/ known helminth infections; treat pre-existing helminth infections before initiating therapy. Seek medical advice if asthma remains uncontrolled or worsens after initiation of treatment. Not recommended to abruptly discontinue corticosteroids after initiation of therapy. Preferable to avoid use during pregnancy. Lactation. Safety & efficacy in childn 6-18 yr have not been established.

Pharyngitis; hypersensitivity reactions; headache; pyrexia, inj site reaction.

Antiasthmatic & COPD Preparations

R03DX10 - benralizumab ; Belongs to the class of other systemic drugs used in the treatment of obstructive airway diseases.

K